Ibrutinib reverses IL-6-induced osimertinib resistance through inhibition of Laminin α5/FAK signaling
Sign Up to like & getrecommendations! Published in 2022 at "Communications Biology"
DOI: 10.1038/s42003-022-03111-7
Abstract: Osimertinib, a 3rd generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), is the first-line standard-of-care for EGFR-mutant non-small cell lung cancer (NSCLC) patients, while acquired drug resistance will inevitably occur. Interleukin-6 (IL-6) is a… read more here.
Keywords: fak signaling; resistance; laminin fak; osimertinib resistance ... See more keywords